Form 4: Ocular Therapeutix Director Hong Seung Suh Receives Stock Options and Restricted Stock Units

Director Hong Seung Suh of Ocular Therapeutix, Inc. was granted stock options and restricted stock units (RSUs) on July 24, 2024.

Summary

• On July 24, 2024, Hong Seung Suh, a director of Ocular Therapeutix, Inc., received stock options and restricted stock units (RSUs).
• The director was granted 36,000 stock options with an exercise price of $7.91, which expire on July 23, 2034.
• The director also received 12,000 RSUs, each representing one share of the company's common stock.
• Both the stock options and RSUs vest 100% on the first anniversary of the grant date or immediately prior to the next annual meeting of stockholders, contingent upon continued service on the board.

Sentiment

Score: 7

Explanation: The document reflects a standard corporate governance practice of granting equity to directors, which is generally viewed positively as it aligns interests. There are no indications of negative news or concerns.

Positives

• The grant of stock options and RSUs aligns the director's interests with those of the shareholders, incentivizing them to work towards the company's success.
• The vesting schedule encourages continued service on the board of directors.

Future Outlook

The vesting of the stock options and RSUs is contingent upon the director's continued service on the board, suggesting an expectation of ongoing involvement.

Industry Context

Grants of stock options and RSUs are common practices in the biotechnology industry to attract and retain qualified board members and align their interests with those of the shareholders.

Comparison to Industry Standards

• Stock option and RSU grants are a standard component of compensation packages for directors in publicly traded companies, particularly in the biotech sector.
• The vesting schedule of one year is fairly typical, aligning with industry norms for incentivizing long-term commitment.
• Comparable companies such as Alimera Sciences and Kala Pharmaceuticals also utilize stock options and RSUs as part of their director compensation packages.

Stakeholder Impact

• Shareholders may view the grant of stock options and RSUs positively as it aligns the director's interests with the company's long-term success.
• The director benefits from the potential future value of the stock options and RSUs.

Key Dates